Prucalopride may enhance cognitive performance in remitted depression

Short‐term treatment improved verbal learning, working‐memory speed, and facial‐expression recognition vs placebo in a randomized trial.

1

Prucalopride treatment for seven to ten days improved cognitive performance in patients with remitted recurrent depression.
2

Improvements were noted in verbal learning, working memory, and facial expression recognition compared to placebo.
3

The strongest effect was observed in verbal learning and memory, with patients recalling more words than those on placebo.
4

Prucalopride was well tolerated, with similar rates of adverse effects compared to placebo, though decreased appetite was more frequent.
5

The study's limitations include a small sample size and a focus on younger, predominantly female participants.

1